Memo Therapeutics AG

We mine the tumor antibody repertoires of elite cancer patients for the identification of novel antibody-target pairs. These tumor-derived antibodies are then used for the development of targeted cancer therapies.
Our proprietary DROPZYLLA® technology is uniquely suited to mine the antibody repertoires of fragile and short-lived tumor-infiltrating B cells. We screen these repertoires using high-throughput genomic and cell-based assays to identify novel antibodies and their targets. Lead antibodies are then developed either as ADC or T-cell engagers. Our initial focus is on lung, ovarian, and colorectal cancer. Our business model focuses on in-house development until clinical proof of concept (phase Ib/II) and out-licensing of preclinical assets to provide non-dilutive funding.